Tocilizumab for COVID-19: a real 'miracle drug'?

Nasim, Sundus; Hashmi, Shariq Haider; Azim, Dua; Kumar, Sohail; Nasim, Jasia

Nasim, Sundus; Hashmi, Shariq Haider; Azim, Dua; Kumar, Sohail; Nasim, Jasia.

Nasim S; Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
Hashmi SH; NYU Grossman School of Medicine, New York City, NY, USA.
Azim D; Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
Kumar S; Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
Nasim J; Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.

Infect Dis (Lond) ; 52(9): 681-682, 2020 09.

Article in English | MEDLINE | ID: covidwho-600905

Subject(s)

Coronavirus Infections; Pandemics; Pneumonia, Viral; Antibodies, Monoclonal, Humanized; Betacoronavirus; COVID-19; Disease Progression; Humans; Retrospective Studies; Risk Factors; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Pandemics Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Infect Dis (Lond) Year: 2020 Document Type: Article Affiliation country: 23744235.2020.1780307

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google